WELCOME TO The Biotechnology REPORT
Moving Analytics Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Research And Markets | June 30, 2020
The "Global Protective Clothing Market for Life Sciences Industry 2019-2028" report has been added to ResearchAndMarkets.com's offering.The publisher predicts that the global market for protective clothing for life sciences industry would witness a CAGR of 6.26% over the forecast period 2019-2028.The growth of this market is primarily being driven by the growing demand for protective clothing from end-users. Additionally, the large investments in research & developm...
TARA Biosystems | November 03, 2021
TARA Biosystemsa, biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.
Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. Thes...
Amyris | October 23, 2020
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...
Cipla | August 24, 2020
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first ste...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE